Now, a cut-price Zytiga from India's BDR Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Months after making news over its compulsory licensing application for Bristol-Myers Squibb's Sprycel (dasatinib), India's BDR Pharmaceuticals, has launched a cut-price version of Johnson & Johnson's metastatic prostate cancer treatment, Zytiga (abiraterone), on the Indian market. And it also supplies the finished product to three more leading firms in India.